SSA
EW icon

Schonfeld Strategic Advisors’s Edwards Lifesciences EW Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,000
Closed -$4.71M – 2654
2022
Q1 		$4.71M Buy
+40,000
New +$4.49M 0.04% 465
2021
Q4 		– Sell
-20,000
Closed -$2.26M – 2253
2021
Q3 		$2.26M Buy
+20,000
New +$2.28M 0.02% 677

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Schonfeld Strategic Advisors's EW Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Edwards Lifesciences (EW) stake by 96% in Q1 2026, selling an estimated $7.75M and leaving 3,411 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Schonfeld Strategic Advisors first reported a position in EW in Q1 2016 and has held it in 29 quarters since. The position peaked at $33.4M in Q1 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Schonfeld Strategic Advisors held 3,411 shares of Edwards Lifesciences worth $273K as of Q1 2026.
  • Schonfeld Strategic Advisors sold 93,980 Edwards Lifesciences shares in Q1 2026, an estimated $7.75M.
  • Edwards Lifesciences made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1615 holding.
  • Schonfeld Strategic Advisors first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 29 quarters since.
  • Schonfeld Strategic Advisors's Edwards Lifesciences position peaked at $33.4M in Q1 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.